Blood Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Blood Screening Market is projected to expand from USD 4.88 Billion in 2025 to USD 6.76 Billion by 2031, registering a CAGR of 5.57%. This market involves the rigorous examination of donated plasma and blood to detect infectious agents and verify compatibility prior to transfusion procedures. The primary drivers for this expansion include the rising worldwide prevalence of infections transmissible via transfusion and stringent regulatory requirements that enforce safety protocols. Additionally, the growing necessity for blood products in trauma and surgical care significantly fuels the need for substantial screening capacities across extensive healthcare networks.

Conversely, the high costs linked to sophisticated molecular testing platforms present an entry barrier for budget-constrained healthcare systems in developing areas. This financial obstacle restricts the uptake of high-end screening technologies, notwithstanding their demonstrated safety advantages. According to the Association for the Advancement of Blood & Biotherapies in March 2025, 11.58 million units of red blood cells were collected in the United States in 2023, highlighting the massive operational magnitude and financial investment necessary to maintain the blood supply in advanced markets.

Market Drivers

The escalating prevalence of chronic and infectious diseases serves as a major stimulant for the blood screening market, requiring strict pathogen identification to guarantee transfusion security. With viral loads rising globally, healthcare infrastructures are urged to adopt rigorous nucleic acid amplification testing (NAT) and immunoassay measures to detect Hepatitis B, Hepatitis C, and HIV prior to their entry into the blood supply. This necessity is emphasized by increasing mortality rates linked to these conditions; according to the World Health Organization's 'Global Hepatitis Report 2024' released in April 2024, viral hepatitis caused 1.3 million deaths in 2022, reinforcing the urgent need for superior screening capabilities to curb transmission via blood products.

Furthermore, the surging global requirement for blood transfusions and donations intensifies the market's dependence on efficient, high-volume screening systems, especially given the fluctuations in donor availability. The imperative to optimize every collected unit promotes the use of automated systems that minimize discard rates and facilitate quick results for emergency cases. However, sustaining sufficient stock remains a major hurdle; the American Red Cross reported in a January 2024 press release that donor numbers have dropped by roughly 40% over the past two decades, leading to a supply crisis that underscores the value of precise screening to avoid waste. To illustrate the scale of diagnostic needs, Roche reported in 2024 that it delivered 29 billion diagnostic tests globally during the previous year.

Market Challenges

The significant costs attached to advanced molecular testing systems act as a major constraint on the Global Blood Screening Market, especially within economically sensitive healthcare sectors in emerging markets. These elevated operational expenses form a substantial barrier to entry, hindering the broad implementation of premium screening technologies that are standard practice in developed countries. As a result, laboratories in resource-poor environments frequently depend on cheaper, outdated testing techniques or skip comprehensive screening altogether. This economic gap directly impedes market progress by restricting the potential customer base for automated instruments and advanced assay kits, effectively limiting revenue opportunities to established, affluent healthcare networks.

Data from the International Society of Blood Transfusion in 2024 revealed that roughly 20% of blood donations in Sub-Saharan Africa went untested for transfusion-transmissible infections due to critical infrastructure and financial limitations. This figure highlights the severe consequences of cost barriers, as the lack of funding for vital screening protocols excludes a large segment of the global population from accessing advanced blood safety measures. As long as these financial constraints continue, the market's growth into developing regions will remain significantly restricted.

Market Trends

The rise of extended blood group genotyping is reshaping the market by facilitating exact donor-recipient matching that exceeds standard ABO and Rh compatibility checks. This evolution is vital for averting alloimmunization in patients requiring chronic transfusions, such as those suffering from sickle cell disease, by detecting minor antigen variations that conventional serology frequently fails to identify. As labs increasingly focus on transfusion safety to reduce adverse events, the demand for sophisticated molecular typing tools has risen sharply. For instance, Grifols reported in February 2025 that it achieved a 10.3% total annual revenue increase at constant currency for 2024, specifically citing its Blood Typing Solutions division as a key contributor with double-digit growth in major markets.

Simultaneously, there is a clear movement toward automated, high-throughput screening systems aimed at optimizing laboratory workflows and handling growing testing loads. By consolidating various assay stages - from sample prep to result interpretation - into unified modular platforms, blood centers can drastically cut manual errors and operating expenses while enhancing turnaround speeds. This trend is reinforced by the necessity for scalable technologies in centralized testing hubs that handle immense volumes of daily samples. According to Roche's 'Annual Report 2024' released in January 2025, Diagnostics Division sales grew by 4%, largely fueled by the robust global adoption of high-throughput molecular and immunodiagnostic solutions that improve lab efficiency.

Key Players Profiled in the Blood Screening Market

• Abbott
• Roche Diagnostics
• Bio-Rad
• Siemens Healthineers
• Grifols
• Ortho Clinical Diagnostics
• QuidelOrtho
• Thermo Fisher
• DiaSorin
• Beckman Coulter

Report Scope

In this report, the Global Blood Screening Market has been segmented into the following categories:

Blood Screening Market, by Technology:

• Nucleic Acid Amplification Test (NAT)
• ELISA
• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
• Next Generation Sequencing (NGS)
• Western Blotting

Blood Screening Market, by Product:

• Reagent
• Instrument

Blood Screening Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Blood Screening Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.